Care Quality Commission
Printable version | E-mail this to a friend |
CQC CALLS FOR RENEWED DRIVE TO CUT PREVALENCE OF ENGLAND’S BIGGEST KILLER: CARDIOVASCULAR DISEASE
Report calls for improvements in statin prescribing, cholesterol management and targeting of poorest areas
The Care Quality Commission (CQC) today (Friday) calls for a renewed drive to cut numbers of people with cardiovascular disease (CVD), which is responsible for one in three deaths in England.
It is publishing a study on efforts to cut deaths from the disease and to reduce inequalities between those in deprived areas and other parts of the country of which CVD is the biggest cause.
The study applauds the decline in England in death rates from the condition, driven by reductions in both smoking and cholesterol levels.
The NHS has encouraged this by increasing both statin prescribing and the proportion of stop-smoking services in GP practices and pharmacies.
The Government has already met its target of cutting total deaths among people under 75 by at least 40 per cent by 2010. It is on track to meet its target of narrowing the gap between worse-off areas and the country as a whole.
But CQC says the nation must go further as the UK still has one of the highest CVD rates in Europe.
It says patients get different standards of care in different areas as many primary care services, including GP practices, do not follow proven practice consistently. It calls for measures to improve further performance of GPs and commissioners on statin prescribing, cholesterol management and targeting of poor areas.
CVD is the name for a group of conditions affecting the heart, arteries or blood vessels – including heart disease and stroke. It is the nation’s biggest killer, causing more than 200,000 deaths annually, a third of the total.
Caused mainly by obesity and smoking, CVD costs the country more than £30 billion a year. It is set to affect greater numbers of people with forecasters predicting that 90 percent of adults will be overweight or obese by 2050.
CQC chair, Barbara Young, said: “This disease is likely to touch every single one of us at some point in our lives. It is good news that the number of deaths has been driven down, but resting on those laurels is really not an option. We cannot accept that more people die here prematurely from CVD than in other countries. And we cannot rest while health inequalities exist on the scale they do. People in the richest area can expect to live up to 23 years longer than people in the poorest.
“We have to raise the bar of acceptable performance, upping the level GPs and primary care practitioners are being asked and incentivized to perform to.
“We must encourage our GP practices and other primary care services to make sure they do what the evidence shows works, making sure they redouble efforts in deprived areas and ensure prescribing is cost-efficient.
“We need GPs and primary care trusts to take up this challenge and we will be encouraging them to do so by sharing our information with them. We will also be using this data in our performance assessments and following up where necessary.”
CQC’s study looks at statin prescribing, which reduces cholesterol levels, and the provision of NHS stop smoking services, which provide advice, support and nicotine-replacement products.
The regulator has, for the first time, collated and analysed data on the performance of some 8,300 GP practices and 152 primary care trusts responsible for the provision and commissioning of this care.
Findings include:
· Giving GPs financial incentives to manage cholesterol levels has improved performance and there is now room for more stretching goals
GPs must record the number of people with heart disease whose cholesterol level is being managed. They get paid when they reach goals on what is known as the Quality and Outcomes Framework (QoF). In 2007/8, overall, 83 per cent of patients with coronary heart disease were recorded as having an acceptable cholesterol level, compared with 72 per cent in 2004/5. Currently, GPs get maximum payment when they record acceptable cholesterol levels for 70 per cent of patients on the register. While there has been improvement, the report shows this is leveling off. Therefore, CQC recommends increasing the payment threshold. It points out that nearly one in five patients on heart disease registers do not have their cholesterol levels recorded as being acceptable and that GP practices can receive maximum payment without doing this for a third of their patients. CQC adds that the national average masks variation in performance - five per cent of GP practices did not reach the maximum payment threshold.
· There is still too much unrecorded CVD and this is particular problem in the most deprived areas of the country
GPs in deprived areas are less likely to record whether someone has CVD. Those not recorded as having the condition may not get access to the services they need. The report estimates that the median (the mid point) unrecorded prevalence across PCTs was 1.1 percent of the total population. This equates to around 350,000 people in England who we would expect to have CVD but who are not recorded as such. The problem is greater in the most deprived areas where estimates suggest that up to seven per cent of the population has CVD that is unrecorded. This is particularly worrying as people in the more deprived areas may have more complex health and social needs and may suffer greater burden of disease before seeking help. CQC says PCTs should use outreach programmes to target people at most risk when commissioning primary care practitioners to carry out vascular screening. The NHS is now offering vascular screening to every adult between the ages of 40 to 74.
· Too many GPs prescribe expensive branded statins when equally effective, cheaper non-branded ones are available.
Statins are the main medicine for lowering cholesterol. NICE recommends that low-cost statins are prescribed where appropriate in the first instance to all adults over the age of 16 who have clinical evidence of CVD and to all those assessed as being at high risk of CVD, but may currently have no symptoms. The NHS spends more on statins than any other drug, with the total cost doubling to some £500 million in the three years to 2007. The study points to analysis by the best practice and training body, the NHS Institute for Innovation and Improvement, which suggests that 78 per cent of statin prescribing should be for generic rather than branded drugs. Therefore, CQC estimates that the cost saving would be ₤62.5m if all GPs prescribed statins in this way. CQC says PCTs should strongly encourage GPs to prescribe non-branded statins, where clinically appropriate, and monitor this systematically. Statin prescribing should be part of an overall care programme that involves lifestyle changes to reduce risk of CVD. PCTs should feed back to GPs any inequalities in prescribing and take action where necessary to ensure prescribing is cost efficient.
· Too many GP practices that are not prescribing cost-efficiently also perform less well on managing patients’ cholesterol levels
CQC looked together at the overall level of statin prescribing and the overall level of cholesterol management. It found that too many practices were in the lower performing category on both counts. The study shows that around one in four practices (approximately 2,000) were in this group. CQC is worried that these practices may be managing CVD less well in terms of both keeping costs down and delivering good outcomes for patients. It says this finding underlines its recommendation that primary care trusts closely monitor prescribing costs and further improve cholesterol management, commissioning services accordingly.
· GPs in deprived areas are less likely to prescribe nicotine-replacement products to patients
Smoking is still the biggest single avoidable cause of death, killing some 82,000 people a year. Overall, levels of smoking have fallen from 28 per cent of the population in 1998 to 21 per cent in 2006, although this masks variations across the population. The study shows that, in deprived areas, the prescribing of nicotine replacement products does not increase in line with greater smoking prevalence. This suggests need is not being met. NICE should recommend extending QoF indicators so that all smokers registered with a GP practice are offered advice or referral to NHS stop-smoking services, as well as medicines that are proven to help. PCTs should monitor how effectively services meet need where it is highest. They should also ensure GPs proactively identify people who live in poorer areas, smoke and at risk of CVD. The Department of Health should collect and publish data on how individual people use services so that performance can be effectively monitored.
· Stop-smoking services in deprived areas need to find more innovative ways of helping people stay off cigarettes
More people use stop smoking services in deprived areas where more people smoke. But at least one in five primary care trusts (PCTs) (37 out of 152) failed to meet NICE guidance that they should get five per cent of the smoking population to take advantage of these services. There is also too much variation between trusts in recruitment and quit rates. For example, the proportion of people who quit for four weeks ranges from just 33 per cent in one PCT to more than 80 per cent in another, with quit rates worse in more deprived areas. Data shows that all but one PCT helped at least 35 per cent of people to quit after four weeks, in line with NICE guidance, but this includes people using the service more than once. CQC recommends that NICE increases both the five per cent and 35 per cent goals. It suggests having more stretching goals in areas where there are more smokers.
For further information please call Sarah Robertson in the CQC press office on 0207 448 9210 or 07917 232 143 after hours.
James Hedges
Media Relations Officer
Care Quality Commission
Finsbury Tower
103-105 Bunhill Row
London
EC1Y 8TG
External: 0207 448 0868
Ext: 3568
Fax: 0207 448 9238
Email: james.hedges@cqc.org.uk
www.cqc.org.uk
“Statutory requests for information made under access to information legislation, such as the Data Protection Act 1998 and the Freedom of Information Act 2000, should be sent to:
information.access@cqc.org.uk”